OTC · NEVPF
Abliva AB (publ)
$0.03$0.00 (0.0%)
Abliva AB (publ)’s quoted price sits in the upper half of its reported 52-week range, 25.13% below the high.
Loading market information…
OTC · ACOGF · USD
Stock price, earnings
Quote as of Nov 25, 2024, 08:00 PM UTC. Cached market data; not a live quote.
One-year closing-price history · USD. Historical prices are not a forecast.
Go beyond this overview with deeper company research in PortfolioX. Explore more in the app
BEHIND THE RESULTS
Upcoming dates and analyst estimates may change. Fiscal quarters follow Alpha Cognition Inc.’s reporting calendar.
THE COMPANY BEHIND THE TICKER
Alpha Cognition Inc. is a clinical-stage biopharmaceutical firm dedicated to pioneering treatments for severe neurological conditions, including Alzheimer's disease and amyotrophic lateral sclerosis (ALS). Its developmental pipeline features ALPHA-1062, an acetylcholine esterase inhibitor designed to address dementia of the Alzheimer's type and mild traumatic brain injury. The company is also advancing ALPHA-0602, a gene therapy candidate specifically for ALS. Founded in 2000, the company initially operated as Crystal Bridge Enterprises Inc. before officially changing its name to Alpha Cognition Inc. in March 2021. The corporate headquarters are located in Vancouver, Canada.
Latest available per-share figures in USD. The payout ratio compares dividends with earnings.
About this data · PortfolioX market data, also available in the mobile app. Prices are displayed in the listing currency; dividend amounts use the currency shown in that section. Data availability and update times vary.
Page generated Oct 30, 2026, 03:05 PM UTC. Quotes retain their own timestamp above. Missing values appear as a dash. This page is for information only, not personalized investment advice.
THE ANALYST VIEW
1 ratings in the current snapshot. Strong buy and strong sell are grouped with buy and sell.
Percentages compare targets with the quoted price when currencies match. Targets are analyst estimates, not guaranteed outcomes.
Consensus coverage: 1 contributors · Median target $20.00.
Average targets in published notes for each window. These figures use a different sample from the consensus above.
HOW THE BUSINESS IS PERFORMING
Statement amounts use the company’s reporting currency and are not converted to the stock’s listing currency. K = thousand, M = million, B = billion, T = trillion. Cash-flow figures are matched by fiscal year; missing figures appear as a dash.
PUT THE NUMBERS IN CONTEXT
Current metrics alongside available historical medians. A lower multiple or higher margin alone does not establish whether a stock is a good investment.
KEEP COMPARING
$0.03$0.00 (0.0%)
Abliva AB (publ)’s quoted price sits in the upper half of its reported 52-week range, 25.13% below the high.
$4.08$0.00 (0.0%)
Relief Therapeutics Holding AG’s quoted price sits in the lower half of its reported 52-week range, 73.06% below the high.
$0.11-$0.01 (-9.69%)
Small Pharma Inc.’s quoted price sits in the lower half of its reported 52-week range, 41.36% below the high.
$0.70-$0.00 (-0.16%)
Enzo Biochem, Inc.’s quoted price sits in the lower half of its reported 52-week range, 41.27% below the high.
CA$0.45-CA$0.01 (-2.17%)
Rocket Doctor AI Inc.’s quoted price sits in the lower half of its reported 52-week range, 54.08% below the high.
$0.17$0.00 (0.0%)
IntelGenx Technologies Corp.’s quoted price sits in the upper half of its reported 52-week range, 0.0% below the high.
£0.03-£0.01 (-12.82%)
ImmuPharma PLC’s quoted price sits in the lower half of its reported 52-week range, 71.31% below the high.
$2.74-$0.01 (-0.27%)
Organicell Regenerative Medicine, Inc.’s quoted price sits in the lower half of its reported 52-week range, 42.86% below the high.
